Premium
The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China
Author(s) -
Huang Junting,
Zhang Yu,
Zhen Zijun,
Lu Suying,
Zhu Jia,
Wang Juan,
Sun Feifei,
Liu Zhuowei,
Gao Yuanhong,
Li Hui,
Zhang Yizhuo,
Sun Xiaofei
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28567
Subject(s) - medicine , histology , wilms' tumor , pathological , biopsy , multivariate analysis , survival rate , oncology , retrospective cohort study , pathology
Purpose : This study aimed to retrospectively analyze survival outcomes for Chinese patients with prechemotherapy blastemal predominant histology type Wilms tumors (WTs). Methods : We collected and analyzed clinical data concerning patients aged <15 years with favorable histology (FH) WTs treated at the Sun Yat‐Sen University Cancer Center from December 2005 to May 2016, based on the Children's Oncology Group protocol. Pathological specimens were collected through biopsy or surgical resection before initiation of chemotherapy. We analyzed survival outcomes involving different prechemotherapy histology subtypes. Results : We enrolled 97 patients with FH WTs (median follow‐up, 71.5 months; range, 22.2‐170.7). The total recurrence rate was 17.5%, and the subtype recurrence rates were as follows: blastemal predominant (45.5%), mixed (7.5%), epithelial (14.3%), and mesenchymal (9.5%) ( P = .010). Five‐year event‐free survival (EFS) and overall survival (OS) rates were 84.9% and 81.4%, respectively. Respective 5‐year EFS and OS rates for subtypes were as follows: blastemal predominant (54.5% and 68.2%), mixed (90.0% and 88.9%), epithelial (85.7% and 85.1%), and mesenchymal (90.5% and 94.7%). Multivariate survival analyses showed that the blastemal predominant subtype was an independent prognostic factor of EFS ( P = .001) and OS ( P = .017). Conclusions : Our findings showed that prechemotherapy blastemal predominant WTs had higher recurrence and lower EFS and OS rates. Our findings suggested that, albeit with some deficiencies, blastemal predominant histology WT–diagnosed prechemotherapy may have prognostic relevance. Further research into other potential confounding variables are required to determine whether such patients warrant altered risk‐stratified therapy.